[ Price : $8.95]
The chairs of two House committees ask FDA for detailed responses to 15 questions about the review and accelerated approval of Bio...[ Price : $8.95]
Takeda Pharmaceutical reports disappointing data from its blood cancer Phase 3 PANTHER (Pevonedistat-3001) study, which did not ac...[ Price : $8.95]
FDA accepts for review an Orphalan NDA for trientine tetrahydrochloride (TETA 4HCl) for the first-line treatment of Wilsons Diseas...[ Price : $8.95]
Attorney Jordan Thomas asks FDA to halt clinical trials of Cassava Sciences simufilam until the agency thoroughly evaluates the sc...[ Price : $8.95]
Federal Register notice: FDA announces an 11/4 Psychopharmacologic Drugs Advisory Committee meeting to discuss a Levo Therapeutics...[ Price : $8.95]
FDA orders a drug class warning for Janus kinase inhibitors after reviewing a recent clinical trial that showed an increased risk ...[ Price : $8.95]
FDA says it may approve returning ranitidine-containing products to the market based on new CDER research into the carcinogen NDMA...[ Price : $8.95]
FDA warns AnazaoHealth that it is compounding drugs that do not meet legal requirements and are considered to be misbranded unappr...